Fig. 8From: Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosisDisease progression is more severe in patients with lower CSF efnA5 protein levels. a Disease onset and b disease progression were determined in patients with CSF efnA5 levels above the median and in patients with CSF efnA5 levels below the median (N = 32). Differences were compared between the two genotypes with the Log-rank test: ** p < 0.01Back to article page